Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 2/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145604 | 0.73 | AR (0.51) | AR | |
| SCHEMBL12604801 | 0.64 | AR (0.39) | ARHSD17B10HPGD | |
| SCHEMBL27943851 | 0.63 | AR (0.48) | SMN1; SMN2ARALDH1A1MAPTKDM4E | |
| SCHEMBL29230410 | 0.62 | MEN1 (0.44) | SMN1; SMN2ARALDH1A1MAPTHPGD | |
| SCHEMBL4131665 | 0.62 | AR (0.47) | SMN1; SMN2AREGFRALDH1A1HSD17B10 | |
| SCHEMBL10914959 | 0.62 | AR (0.44) | SMN1; SMN2ARALDH1A1HSD17B10MAPT | |
| SCHEMBL26215545 | 0.62 | BACE1 (0.38) | ARTRPV1HCAR1TRPA1TRPM8 | |
| SCHEMBL30449773 | 0.60 | BACE1 (0.64) | ARALDH1A1GAAMAPTKDM4E | |
| SCHEMBL895250 | 0.60 | BACE1 (0.64) | ARALDH1A1GAAMAPTKDM4E | |
| SCHEMBL2852804 | 0.60 | ABCC8 (0.47) | SMN1; SMN2ARALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | SMN1; SMN2 4862/4885AR 1/4885EGFR 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.